Coverage and Payment for the Subcutaneous Implantable Defibrillator (S-ICD™) System

In the spring of 2017,  the HRS Subcommittee on Reimbursement and Regulatory Affairs released a statement recommending that private payers provide coverage for subcutaneous implantable cardiac defibrillator (S-ICD) therapy, consistent with FDA labeling.

Coverage and Payment for the Subcutaneous Implantable Defibrillator (S-ICD™) System 233.56 kB